Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
International consensus has not yet been reached for the use of preoperative chemotherapy for localized esophageal cancer. Chong and Cunningham give an overview of the latest trials and meta-analyses, discussing possible reasons for discrepant findings, and giving their interpretation of best clinical practice for this disease.
Recent improvements in the development of antiemetics have helped to minimize chemotherapy-induced nausea and vomiting. Oo and Hesketh review the latest clinical trial data and discuss how the introduction of two new antiemetics, palonosetron, a 5-HT3 antagonist, and aprepitant, a NK-1 antagonist, have demonstrated significant advances for patients inadequately controlled with conventional antiemetic regimens.
Discovery of molecular pathways critical to carcinogenesis is revolutionizing the treatment and prevention of cancer. This review discusses recent advances in colorectal cancer chemoprevention and the development of novel anti-inflammatory agents that target signaling pathways important in tumor formation and metastasis, such as those involving cyclooxygenase (COX1 and COX2) and the epidermal growth factor receptor (EGFR).
Intensity-modulated radiation therapy (IMRT) has advantages over standard radiotherapy techniques, but few studies have been performed in pediatric cancer patients, and as a result radiation oncologists have not universally accepted its use. This review discusses the current and future applications of IMRT in pediatric malignancies and its potential pitfalls, and highlights the radiotherapeutic options available for pediatric patients unsuitable for conventional radiotherapy.
